[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.129.96. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Citations 0
Correction
August 19, 1998

Error in Text

JAMA. 1998;280(7):604. doi:10.1001/jama.280.7.604

In the Contempo 1998 article entitled "Memory Loss—When Is It Alzheimer Disease?" published in the June 3, 1998, issue of THE JOURNAL (1998;279:1689-1690), the second sentence of the last paragraph, "Currently, pharmacologic approaches include acetylcholinesterase inhibitors (eg, donepezil) that result in improved alertness and behavior in approximately 5% of patients," is incorrect. The following sentences should be substituted: "Currently, pharmacologic approaches include acetylcholinesterase inhibitors (eg, donepezil), which result in improved alertness and behavior. In 2 recent randomized controlled trials of 24 and 12 weeks' duration, 25% and 38% of patients with mild to moderate Alzheimer disease treated with 10 mg/d of donepezil demonstrated improvement on a measure of global function compared with 11% and 18% of patients treated with placebo, respectively. Statistically significant improvement in cognitive function was also observed in the treatment groups compared with the groups receiving placebo (Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, and the Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 1998;50:136-145; Rogers SL, Doody RS, Mohs RC, Friedhoff LT, and the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med. 1998;158:1021-1031).”

×